A_phase_II_study_of_mitoxantrone,_etoposide,_and_thiotepa_with_autologous_marrow_support_for_patients_with_relapsed_breast_cancer._To_further_improve_the_effect_of_high-dose_chemotherapy_in_the_treatment_of_locally_advanced_and_metastatic_breast_cancer,_we_sought_to_develop_a_second_active_high-dose_noncross-resistant_regimen_to_use_in_tandem_with_our_customary_high-dose_regimen_of_cyclophosphamide,_etoposide,_and_cisplatin_(CVP)._We_performed_a_phase_II_trial_of_high-dose_mitoxantrone_30_mg/m2,_etoposide_200_mg/m2_every_12_hours_x_6,_and_thiotepa_250_mg/m2_x_3_days_(MVT)_in_31_patients_with_heavily_pretreated_metastatic_breast_cancer_and_one_with_locally_advanced_chemotherapy-refractory_breast_cancer._These_patients_were_ineligible_for_high-dose_CVP_chemotherapy_because_of_the_amount_of_prior_treatment_and_poor-response_status._Of_the_32_patients,_14_responded_to_cycle_1,_did_not_experience_any_grade_4_toxicity,_and_received_a_second_cycle_of_MVT._Overall,_seven_of_31_patients_achieved_a_complete_response_(CR;_23%)._Four_of_the_14,_who_were_partial_responders_to_the_first_cycle,_achieved_a_CR_after_the_second_cycle._The_overall_response_rate_was_19_of_31_(61%)_with_an_overall_median_freedom_from_progression_of_4_to_5_months_and_an_overall_median_survival_of_9_months._Toxicity_consisted_primarily_of_mucositis_(grade_3_or_4_in_69%)._The_results_indicate_that_high-dose_MVT_produces_significant_activity,_even_in_heavily_pretreated_patients._Administration_of_a_second_cycle_of_high-dose_therapy_with_MVT_increased_the_CR_rate,_and_the_morbidity_and_mortality_from_the_second_cycle_were_not_greater_than_that_for_the_first_cycle._Because_of_the_high_incidence_of_grade_3_or_4_mucositis_with_this_regimen,_we_are_currently_completing_a_follow-up_study_of_high-dose_mitoxantrone_and_thiotepa_alone.